Trial Profile
A Phase II Trial to Investigate the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 27 Sep 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Rituximab (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- Acronyms PembroWM
- 13 Dec 2022 Status changed from recruiting to discontinued, according to presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 13 Dec 2022 Results assessing safety, tolerability and efficacy of pembrolizumab in combination with rituximab for the treatment of relapsed/refractory Waldenstroms macroglobulinaemia, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 17 May 2021 Planned End Date changed from 1 Mar 2023 to 1 Dec 2023.